Seres Therapeutics (MCRB) Non-Current Debt (2019 - 2024)
Historic Non-Current Debt for Seres Therapeutics (MCRB) over the last 7 years, with Q2 2024 value amounting to $102.5 million.
- Seres Therapeutics' Non-Current Debt rose 173.91% to $102.5 million in Q2 2024 from the same period last year, while for Jun 2024 it was $102.5 million, marking a year-over-year increase of 173.91%. This contributed to the annual value of $101.5 million for FY2023, which is 10071.55% up from last year.
- According to the latest figures from Q2 2024, Seres Therapeutics' Non-Current Debt is $102.5 million, which was up 173.91% from $102.0 million recorded in Q1 2024.
- In the past 5 years, Seres Therapeutics' Non-Current Debt ranged from a high of $102.5 million in Q2 2024 and a low of $16.1 million during Q3 2021
- Moreover, its 5-year median value for Non-Current Debt was $50.5 million (2022), whereas its average is $52.4 million.
- Its Non-Current Debt has fluctuated over the past 5 years, first plummeted by 3547.26% in 2021, then surged by 21554.88% in 2022.
- Seres Therapeutics' Non-Current Debt (Quarter) stood at $24.6 million in 2020, then increased by 0.02% to $24.6 million in 2021, then surged by 105.3% to $50.6 million in 2022, then skyrocketed by 100.72% to $101.5 million in 2023, then increased by 0.94% to $102.5 million in 2024.
- Its Non-Current Debt was $102.5 million in Q2 2024, compared to $102.0 million in Q1 2024 and $101.5 million in Q4 2023.